 |
1 Company | 1 Product |
|
|
1 Product | |
2 Diseases | |
1 Trial |  |
8 News |  |
| «12...4567891011121314...3233» |
- | Preclinical, Journal: Cellulose ether treatment inhibits amyloid beta aggregation, neuroinflammation and cognitive deficits in transgenic mouse model of Alzheimer's disease. (Pubmed Central) - Aug 2, 2023
pathologies and cognitive impairments, and direct, potent anti-inflammatory activity to rescue neuroinflammation. Therefore, these FDA-approved compounds are effective candidates for developing therapeutics for AD and related neurodegenerative diseases associated with protein misfolding.
- | Cognex (tacrine) / Shionogi
Journal: Modified Tacrine Derivatives as Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Synthesis, Biological Evaluation, and Molecular Modeling Study. (Pubmed Central) - Jul 31, 2023
It was shown that 5c and 5d were blood-brain barrier (BBB) penetrants by online prediction. Taken together, these multifunctional properties highlight that compounds 5c and 5d can serve as promising candidates for the further development of multifunctional drugs against AD.
- | Journal: Ethyl acetate extract of Gastrodia (Pubmed Central) - Jul 31, 2023
The present research results demonstrated that the protective effect of EEGE on transgenic C. elegans was to reduce A? protein aggregation, improve the in vivo antioxidant level, effectively remove free radicals and to regulate the expression of genes related to IIS pathway, thereby reducing A?-induced toxicity and delaying nematode paralysis.
- | donepezil / Generic mfg., rivastigmine / Generic mfg.
Journal: Design and development of benzyl piperazine linked 5-phenyl-1,2,4-triazole-3-thione conjugates as potential agents to combat Alzheimer's disease. (Pubmed Central) - Jul 30, 2023
The 100 ns molecular dynamics simulation studies of compound PD-22 complexed with AChE and BACE-1 enzymes suggested stable ligand-protein complex throughout the simulation run. Based on our findings compound PD-22 could further be utilized as a lead to design a promising candidate for AD therapy.
- | piceatannol / New York Medical College, Kyushu University
Preclinical, Journal: Inhibition of Acetylcholinesterase and Amyloid-? Aggregation by Piceatannol and Analogs: Assessing In Vitro and In Vivo Impact on a Murine Model of Scopolamine-Induced Memory Impairment. (Pubmed Central) - Jul 29, 2023
The RHA and isoRHA at 10 ?M were proven to stimulate neurite outgrowths in the SH-SY5Y cell models. These results reveal that nutraceuticals or functional foods containing PIC have the potential for use in the treatment of neurodegenerative disorders.
- | Preclinical, Journal: Synthesis and evaluation of curcumin-based near-infrared fluorescent probes for detection of amyloid ? peptide in Alzheimer mouse models. (Pubmed Central) - Jul 29, 2023
pathological changes. The fluorescent probes designed in this study can become an effective tool for early AD diagnosis and visual detection.
- | Journal: Macrophage membrane-encapsulated nitrogen-doped carbon quantum dot nanosystem for targeted treatment of Alzheimer's disease: Regulating metal ion homeostasis and photothermal removal of ?-amyloid. (Pubmed Central) - Jul 28, 2023
fibrils to protect cells from A? neurotoxicity, providing an effective strategy for A?-targeted treatment of AD.
- | Journal: Interrogation of human microglial phagocytosis by CRISPR genome editing. (Pubmed Central) - Jul 28, 2023
CRISPR genome editing by Cas9 RNP electroporation is a robust approach to genetically modify HMC3 for functional studies such as the interrogation of A? and tumor phagocytosis, and is readily adoptable to investigate other aspects of microglial biology.
- | Journal: "Common-Precursor" Protein Mimetic Approach to Rescue A? Aggregation-Mediated Alzheimer's Phenotypes. (Pubmed Central) - Jul 24, 2023
Moreover, RD242 was very effective in rescuing AD phenotypes in a post-disease onset AD model. We envision that our "common-precursor" synthetic approach will have tremendous potential as it is expandable for other oligoamide scaffolds to enhance affinity for disease-relevant targets.
- | Journal: An activatable small-molecule fluorogenic probe for detection and quantification of beta-amyloid aggregates. (Pubmed Central) - Jul 22, 2023
Besides, cell staining results confirmed that SK-N-BE(2) cells can be fluorescently lighted up as well as cell permeability and damage when treated with BPM1-bound A? aggregates.
- | Journal: An AIE-Active NIR Fluorescent Probe with Good Water Solubility for the Detection of A? Aggregates in Alzheimer's Disease. (Pubmed Central) - Jul 18, 2023
It is believed that the probe reported in this work should be useful for the sensitive detection and accurate localization mapping of A? aggregates related to Alzheimer's disease.
- | Journal: An ankyrin repeat chaperone targets toxic oligomers during amyloidogenesis. (Pubmed Central) - Jul 11, 2023
The substrate-binding domain of cpSRP43, composed primarily of the ARD, is necessary and sufficient to prevent A?42 aggregation and to protect cells against A?42 toxicity. This work provides an example in which an ARD chaperone non-native to mammalian cells harbors anti-amyloidal activity, which may be exploited for bioengineering.
- | RSL3 / Stanford University
Journal, IO biomarker: Design, synthesis and biological evaluation of new multi-target scutellarein hybrids for treatment of Alzheimer's disease. (Pubmed Central) - Jul 10, 2023
Notably, 11e significantly reduced ?-amyloid precursor protein (APP) and ?-site APP cleaving enzyme-1 (BACE-1) protein expression in brain tissue of scopolamine-treated mice. Taken together, these outstanding properties qualified compound 11e as a promising multi-target candidate for AD therapy, worthy of further studies.
- | Leqembi (lecanemab-irmb) / Biogen, BioArctic, Eisai
Journal: Abundant A? fibrils in ultracentrifugal supernatants of aqueous extracts from Alzheimer's disease brains. (Pubmed Central) - Jul 10, 2023
aggregate-directed antibody reported to improve AD cognitive outcomes...We conclude that fibrils are abundant in aqueous extracts from AD brains and have the same structures as those from plaques. These findings have implications for AD pathogenesis and drug design.
- | Journal: ?2-Microglobulin boosts ?-amyloid aggregation and neurotoxicity in an Alzheimer's disease model. (Pubmed Central) - Jul 7, 2023
These findings have implications for AD pathogenesis and drug design. No abstract available
- CSF sTREM2 and YKL-40 modify the balance between soluble and fibrillary ?-amyloid in non-demented individuals (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_8531;
deposition in individuals with decreased soluble A? , astroglial reactivity (as measured by CSF YKL-40) may have the opposite effect.
- Sulfanegen, a 3-mercaptopyruvate sulfurtransferase substrate, as a therapeutic option for Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7887;
Collectively, our results show that the provision of a 3MST substrate, sulfanegen, exhibits neuroprotective effects, along with restoration of cognitive function in an AD mouse model. This study suggests an important role of 3MST in AD pathophysiology and potential therapeutic utility of sulfanegen as a disease-modifying treatment.
- The association between A? aggregation and age depends on APOE genotype: Findings from the AMYPAD cohort (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7682;
The effect of APOE4 on A? deposition was global rather than regional in our analysis.
- Palmitoyl transferase zDHHCs: novel targets in Alzheimer's disease (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7618;
This is the first preclinical study on the effect of 2BP treatment on AD-related cognitive decline. Our data indicate that aberrant palmitoylation plays a critical role in the onset and progression of AD and unveil the potential druggable role of zDHHC enzymes in dementia-related neurodegenerative disorders.
- Age- and Sex- dependent changes in Translocator Protein 18 kDa (TSPO) expression, cellular sources, and association with amyloid-? plaques in the 5XFAD murine model of Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7550;
These results indicate that brain TSPO is an early biomarker of neuroinflammation and TSPO levels increase at the same time that A?-aggregation and much earlier than cognitive decline. Furthermore, the increase in TSPO levels was associated with microglia surrounding or embedded with A?-plaques suggesting a role in plaque formation.
- The pTau interactome in sporadic Alzheimer's disease across APOE genotypes (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7169;
Our proteomic data highlighted an influence of the APOE polymorphism on pTau metabolism. These results will be validated in the human brain using histological and biochemical methods, paving the way to the identification of new therapeutic targets for AD.
- Influence of Epigallocatechin gallate stabilized Gold nanoparticles in amyloid beta fibril inhibition (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_7055;
These results will be validated in the human brain using histological and biochemical methods, paving the way to the identification of new therapeutic targets for AD. This work provides new insights into the synthesised AuNps as functional therapeutic agent for AD.
- Modeling neuropathology of Alzheimer (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_6290;
formation reduces tauopathy and neuronal cell death. Our unique patient specific 3D model system provides opportunities to investigate the interplay between AD pathological events and could serve as a platform for screening compounds and developing personalized therapeutics for AD.
- Leveraging the full potential of Raman spectroscopy for the identification of amyloid aggregation states (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_6212;
aggregates. Thus, this study provides a guideline for extracting comprehensive knowledge from spectroscopic data on peptide aggregation, potentially ser ving as a non-destructive, quic k addition or alternative to more established methods.
- Sulfanegen, a 3-mercaptopyruvate sulfurtransferase substrate, as a therapeutic option for Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_5821;
Collectively, our results show that the provision of a 3MST substrate, sulfanegen, exhibits neuroprotective effects, along with restoration of cognitive function in an AD mouse model. This study suggests an important role of 3MST in AD pathophysiology and potential therapeutic utility of sulfanegen as a disease-modifying treatment.
- The association between A? aggregation and age depends on APOE genotype: Findings from the AMYPAD cohort (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_5616;
The effect of APOE4 on A? deposition was global rather than regional in our analysis.
- Palmitoyl transferase zDHHCs: novel targets in Alzheimer's disease (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_5552;
This is the first preclinical study on the effect of 2BP treatment on AD-related cognitive decline. Our data indicate that aberrant palmitoylation plays a critical role in the onset and progression of AD and unveil the potential druggable role of zDHHC enzymes in dementia-related neurodegenerative disorders.
- Age- and Sex- dependent changes in Translocator Protein 18 kDa (TSPO) expression, cellular sources, and association with amyloid-? plaques in the 5XFAD murine model of Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_5484;
These results indicate that brain TSPO is an early biomarker of neuroinflammation and TSPO levels increase at the same time that A?-aggregation and much earlier than cognitive decline. Furthermore, the increase in TSPO levels was associated with microglia surrounding or embedded with A?-plaques suggesting a role in plaque formation.
- The pTau interactome in sporadic Alzheimer's disease across APOE genotypes (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_5103;
Our proteomic data highlighted an influence of the APOE polymorphism on pTau metabolism. These results will be validated in the human brain using histological and biochemical methods, paving the way to the identification of new therapeutic targets for AD.
- Influence of Epigallocatechin gallate stabilized Gold nanoparticles in amyloid beta fibril inhibition (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_4988;
These results will be validated in the human brain using histological and biochemical methods, paving the way to the identification of new therapeutic targets for AD. This work provides new insights into the synthesised AuNps as functional therapeutic agent for AD.
- ?7 Nicotinic acetylcholine receptor as an early modulator linking reactive astrogliosis, cholinergic and the amyloid cascade hypothesis in AD (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_4027;
Furthermore, our multi-tracer approach using [ 3 H]-KIn83, [ 3 H]-L-deprenyl and [ 3 H]-PIB in APPswe mouse brains will indicate whether the interplay between reactive astrogliosis and ?7nAChRs overexpression may trigger A? deposition in AD.
- Different astrocyte phenotypes mediate the pathological cascade early in the Alzheimer's disease continuum (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3959;
On the other hand, those releasing YKL-40 into the CSF appear to play a role later in the pathological cascade, mediating downstream tau pathology and neuronal damage. These results indicate that different astrocyte phenotypes are specifically involved in distinct stages of the early pathological cascade in preclinical AD.
- sirolimus / Generic mfg.
The development of therapeutic nanovaccine that elicits anti-A? antibodies and A?-specific regulatory T cells for the treatment of Alzheimer (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3875;
proposes a novel approach to AD treatment that achieves synergistic therapeutic efficacy by combining the mode of action of anti-A? antibodies and A?-specific Treg cells.
- Amyloid Against Amyloid: Dimeric Amyloid Fragment Ameliorates Cognitive Impairments by Direct Clearance of Oligomers and Plaques (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3871;
antibodies and A?-specific Treg cells. Overall, we designed a dimeric A?(1
- Different astrocyte phenotypes mediate the pathological cascade early in the Alzheimer's disease continuum (Hall 2) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3806;
On the other hand, those releasing YKL-40 into the CSF appear to play a role later in the pathological cascade, mediating downstream tau pathology and neuronal damage. These results indicate that different astrocyte phenotypes are specifically involved in distinct stages of the early pathological cascade in preclinical AD.
- Sulfanegen, a 3-mercaptopyruvate sulfurtransferase substrate, as a therapeutic option for Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3575;
Collectively, our results show that the provision of a 3MST substrate, sulfanegen, exhibits neuroprotective effects, along with restoration of cognitive function in an AD mouse model. This study suggests an important role of 3MST in AD pathophysiology and potential therapeutic utility of sulfanegen as a disease-modifying treatment.
- The association between A? aggregation and age depends on APOE genotype: Findings from the AMYPAD cohort (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3370;
The effect of APOE4 on A? deposition was global rather than regional in our analysis.
- Palmitoyl transferase zDHHCs: novel targets in Alzheimer's disease (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3306;
This is the first preclinical study on the effect of 2BP treatment on AD-related cognitive decline. Our data indicate that aberrant palmitoylation plays a critical role in the onset and progression of AD and unveil the potential druggable role of zDHHC enzymes in dementia-related neurodegenerative disorders.
- Age- and Sex- dependent changes in Translocator Protein 18 kDa (TSPO) expression, cellular sources, and association with amyloid-? plaques in the 5XFAD murine model of Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_3238;
These results indicate that brain TSPO is an early biomarker of neuroinflammation and TSPO levels increase at the same time that A?-aggregation and much earlier than cognitive decline. Furthermore, the increase in TSPO levels was associated with microglia surrounding or embedded with A?-plaques suggesting a role in plaque formation.
- The pTau interactome in sporadic Alzheimer's disease across APOE genotypes (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_2857;
Our proteomic data highlighted an influence of the APOE polymorphism on pTau metabolism. These results will be validated in the human brain using histological and biochemical methods, paving the way to the identification of new therapeutic targets for AD.
- Influence of Epigallocatechin gallate stabilized Gold nanoparticles in amyloid beta fibril inhibition (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_2743;
These results will be validated in the human brain using histological and biochemical methods, paving the way to the identification of new therapeutic targets for AD. This work provides new insights into the synthesised AuNps as functional therapeutic agent for AD.
- Induction of plaque-like A? aggregates in human iPSC-derived mixed cell type neurospheres as a model to study Ab-microglia interaction (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1820;
This work provides new insights into the synthesised AuNps as functional therapeutic agent for AD. We here present a reproducible human 3D cell culture model allowing the formation of equally sized neurospheres in large batches and believe this to be a perfect tool to understand the underlying mechanisms of A
- A Novel Method for Detecting Protein Aggregates Using Plasmonic Sensing (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1813;
The AuNP dimerisation when A? aggregates are present is also interesting, and may serve as further verification of the size or shape of these aggregates.
- The role of Alzheimer (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1810;
aggregates and will help to better understand how ApoE isoforms affect A? aggregation.
- Nicotinic ACh receptor activation induces BACE1 transcription via MEK?ERK-SP1 signaling pathway (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1809;
Thus, nicotine could have opposite effects on brain A? deposition, which may explain inconsistency of previous studies on nicotine and Alzheimer disease.
- The Effect of an Amyloid Modifier SERF1a on Amyloid-? Fibrillization (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1807;
The cytotoxicity caused by SERF1a-accelerated A? oligomers can be rescued by SERF1a antibody.
- Human and mouse seeds differentially affect A? aggregation by modulating the inflammatory response (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1775;
Therefore, more profound understanding these factors will provide key insight on how amyloid pathology progresses in AD. Grant support: This study was supported by Minister of Science and Innovation grant PID2019-108911RA-100 (D.B.V.), Alzheimer
- Can an online battery match in-person cognitive testing in predicting age-related cortical changes (In-Person) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1716;
accumulation accelerate cognitive ageing potentially before translation into structural brain changes. Adequate sensitivity of online cognitive tests for studying age-related neurobiology of cognition is suggested.
- Sulfanegen, a 3-mercaptopyruvate sulfurtransferase substrate, as a therapeutic option for Alzheimer (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1355;
Collectively, our results show that the provision of a 3MST substrate, sulfanegen, exhibits neuroprotective effects, along with restoration of cognitive function in an AD mouse model. This study suggests an important role of 3MST in AD pathophysiology and potential therapeutic utility of sulfanegen as a disease-modifying treatment.
- The association between A? aggregation and age depends on APOE genotype: Findings from the AMYPAD cohort (Virtual) - Jul 6, 2023 - Abstract #AAIC2023AAIC_1150;
The effect of APOE4 on A? deposition was global rather than regional in our analysis.